Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Azelio in connection with its capital raising and listing on Nasdaq First North
Mandate

Vinge advises Azelio in connection with its capital raising and listing on Nasdaq First North

December 10, 2018 Capital Markets and Public M&A

Vinge has advised Azelio AB (publ) (“Azelio”) in connection with its capital raising and listing on Nasdaq First North.

The prospectus was published on 19 November 2018 and the trading on Nasdaq First North began on 10 December 2018. The total value of the offering amounted to approximately SEK 278 million, assuming that the over-allotment option is fully exercised.

Azelio is a technology company that offers a system of Stirling engine-based concentrated solar power with thermal energy storage that enables electricity production around the clock. The company has its head office in Gothenburg, Sweden, with production in Uddevalla and a development center in Gothenburg and Åmål, as well as a sales office in Beijing, China and a representative office in Madrid, Spain. As of September 30, 2018, the company had 75 employees.

Vinge’s team primarily consisted of Jesper Schönbeck, Joakim Hagberg, William Kåge and Elisabet Hallberg.

Related

Vinge advises Sobro on its investment in Västkustens Konstruktionsbyrå

 Västkustens Konstruktionsbyrå has decided to broaden its ownership structure by bringing in Sobro as a new co-partner and majority shareholder. The founders will remain with the company as the CEO and CTO respectively, and as significant shareholders. Västkustens Konstruktionsbyrå is an engineering consultancy company based in Gothenburg with cutting-edge expertise in project management, civil engineering and design.
April 23, 2026

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

 Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026